Inhibikase Therapeutics, Inc. announced the company has completed enrollment in the Phase 2 ?201? trial evaluating the safety and tolerability of risvodetinib (?risvo?), a potent selective c-Abl inhibitor, for treatment in untreated Parkinson?s patients. The company expects to report trial results in the fourth quarter of 2024.

The 201 Trial is a 12-week, randomized, double-blind, multi-center, placebo-controlled clinical trial evaluating three risvo doses in patients with untreated Parkinson?s disease to assess safety, tolerability and efficacy of risvo in untreated Parkinson?s disease. The trial has enrolled all 120 participants across 32 sites across the United States, and expects to randomize 126 patients total so as not to exclude already screened participants from participating in the trial. As of June 17, 2024, 69 participants have completed the 12-week dosing period.

To-date, there have been 32 mild and 5 moderate adverse events observed that may be related to risvo treatment. Four people withdrew from the trial without completing 12 weeks of treatment.